Engineered Therapeutics, Department of Advanced Organ bioengineering and Therapeutics, Technical Medical Centre, University of Twente, Enschede, The Netherlands.
Department of Medical BioSciences (MBS), Radboud University Medical Center, Nijmegen, The Netherlands.
Eur J Pharm Biopharm. 2024 Nov;204:114510. doi: 10.1016/j.ejpb.2024.114510. Epub 2024 Sep 21.
Tumor-associated innate immune cells such as tumor-associated macrophages, neutrophils, dendritic cells play a crucial role in tumor progression, angiogenesis and metastasis. These cells also control the efficacy of chemotherapy and immunotherapy by inducing drug resistance and immunosuppression, leading to therapeutic failures. Therefore, targeting the tumor-associated innate immune cells has gained high attention for the development of effective cancer therapy. Nanomedicine based strategies to target these cells are highly relevant and can be used to reprogram these cells. In this review, we discuss the fundamental roles of the tumor-associated innate immune cells in the tumor microenvironment and different strategies to modulate them. Then, nanomedicine-based strategies to target different tumor innate immune cells are explained in detail. While the clinical development of the targeted nanomedicine remains a great challenge in practice, we have provided our perspectives on various factors such as pharmaceutical aspects, preclinical testing and biological aspects which are crucial to consider before translating these targeting strategies to clinics.
肿瘤相关的固有免疫细胞，如肿瘤相关巨噬细胞、中性粒细胞、树突状细胞，在肿瘤进展、血管生成和转移中发挥着关键作用。这些细胞还通过诱导耐药性和免疫抑制来控制化疗和免疫疗法的疗效，导致治疗失败。因此，针对肿瘤相关固有免疫细胞的治疗策略已成为开发有效癌症治疗方法的重点。基于纳米医学的靶向这些细胞的策略具有高度相关性，可以用于重新编程这些细胞。在这篇综述中，我们讨论了肿瘤相关固有免疫细胞在肿瘤微环境中的基本作用以及不同的调节策略。然后，详细解释了基于纳米医学的靶向不同肿瘤固有免疫细胞的策略。虽然靶向纳米医学的临床发展在实践中仍然是一个巨大的挑战，但我们已经就各种因素提供了观点，如药物方面、临床前测试和生物学方面，这些因素在将这些靶向策略转化为临床应用之前是至关重要的。
